1 / 11

Screening of Human and Animal S era from Egypt and Hong Kong

Screening of Human and Animal S era from Egypt and Hong Kong. Sampled 1343 Human, 625 animals. Perera et al. Euro Surveill. 2013;18(36):pii=20574. Treatment. SARS: definitive treatment regimen was not clearly established MERS CoV : Interferon alpha 2b + ribavirin in vitro 1

mave
Download Presentation

Screening of Human and Animal S era from Egypt and Hong Kong

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Screening of Human and Animal Sera from Egypt and Hong Kong Sampled 1343 Human, 625 animals Perera et al. Euro Surveill. 2013;18(36):pii=20574

  2. Treatment • SARS: definitive treatment regimen was not clearly established • MERS CoV: Interferon alpha 2b + ribavirin in vitro1 • Recent study in Macaque monkeys2 • No clear data on human treatment 1Falzarano D et al. Sci Rep 3 2013:1686 2Falzarano D et al. Nature Medicine 2013 pub online 9/8/13

  3. Vaccines • SARS vaccines were in development • Possible MERS vaccines: • VLP/nanoparticles with S protein • Constitutive expression of S protein in cell culture • Developmental stages

  4. Domestic Activities • Case definition and guidance developed and disseminated • 5 MMWRs published • 3 health advisories sent to state/local health departments • Investigating persons with travel link, severe respiratory illness • 100 samples/31 states: all negative • Serology developed • MERS-CoV ELISA, MERS-CoV IFA and MERS-CoV MNt • PCR diagnostics developed and distributed

  5. CDC Case Definition Patient Under Investigation (PUI) • A person with the following characteristics: • Fever (≥38°C, 100.4°F) and pneumonia or acute respiratory distress syndrome (based on clinical or radiological evidence); • AND EITHER • History of travel from countries in or near the Arabian Peninsula within 14 days before symptom onset; • OR • Close contact with a symptomatic traveler who developed fever and acute respiratory illness (not necessarily pneumonia) within 14 days after traveling from countries in or near the Arabian Peninsula; • OR • Is a member of a cluster of patients with severe acute respiratory illness (e.g. fever and pneumonia requiring hospitalization) of unknown etiology in which MERS-CoV is being evaluated, in consultation with state and local health departments. http://www.cdc.gov/coronavirus/mers/case-def.html

  6. Epidemiology Tool KitPatient Under Investigation Form

  7. Surveillance Plan: Phasic Response Tiers

  8. Domestic Deployment of CDC MERS-CoV rRT-PCR Assay by LRN Approved for MERS-CoV testing (44) Kits will be sent later (6)

  9. Infection Prevention and Control Recommendations • Standard, Contact and Airborne Precautions • N95 respirators if available • Airborne infection isolation rooms • Similar recommendations as SARS • High mortality • Human-to human transmission • Unknown modes of transmission • No vaccine or chemoprophylaxis

  10. Infection Control: Checklists • Prompt triage and testing of patients • Prioritization of available isolation rooms • Plans for appropriate cohorting of patients and personnel • Training • Sick leave policy

More Related